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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 100mg 
Flibanserin is effective in increasing the number of sexually satisfying events in women with 
HSDD. 
 
STUDY DESIGN: Review of three, placebo-controlled trials in which women > 18 years old 
with HSDD were treated with either 100mg Flibanserin or a Placebo once daily qhs for 24 weeks 
 
DATA SOURCES: Three randomized, placebo-controlled trials found via PubMed searches and 
published in English peer-reviewed journals between 2011-2014 
 
OUTCOMES MEASURED: Outcomes measured were the number of SSE over 4 weeks and 
analyzed with Wilcoxon’s rank-sum test. 
 
RESULTS: In DeRogatis et al, 100mg Flibanserin led to increases in the mean (standard error) 
SSE 1.6 (0.23) vs 0.80 (0.20) and was proven to be statistically significant (p<0.01). AEs led to 
6.8% of 100mg Flibanserin subjects vs. 3.4% of Placebo subjects to discontinue the study 
medication. In Katz et al, 100mg Flibanserin led to increases in the mean (standard deviation) 
SSE of 2.5(4.6) vs 1.5(4.5) with a p value <0.001. AEs led to 9.76% of Flibanserin subjects vs. 
3.47% of subjects on Placebo to discontinue study medications. In Simon et al, 100mg 
Flibanserin led to increases in in the mean (standard error) SSE 1.0 (0.1) vs. 0.6 (0.1) and was 
statistically significant with p=0.004. 8.1% of Flibanserin subjects discontinued study medication 
due to AEs while on 3.1% of Placebo subjects. 
 
CONCLUSIONS: Based on this review, 100mg Flibanserin taken once daily qhs is effective and 
well tolerated in treating those with HSDD in both pre- and postmenopausal women. The mean 
number of SSE was statistically significant vs. placebo in all three studies. 
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INTRODUCTION 
 Hypoactive Sexual Desire Disorder (HSDD) can be clinically characterized as a lack of 
sexual fantasies or desire for sexual activity that leads to marked distress and interpersonal 
relationship difficulties.1 Women with HSDD have described feeling less physically and 
emotionally satisfied in a relationship as well as generally less happy.1 This paper evaluates three 
randomized, double blind, placebo controlled studies that determined if 100mg Flibanserin was 
effective at increasing the number of sexually satisfying events (SSE) in women with HSDD.  
It is estimated that nearly 10% of all premenopausal women aged 18-55 years old suffer 
from a sexual dysfunction disorder.1,2 Women with HSDD are often underreported due to the 
difficult nature of diagnosing HSDD and the need to exclude other medical conditions or 
psychosocial history.1,2 The exact cause of HSDD is unknown but it is thought that both 
biological and psychosocial factors play a role. Biologically, it is thought that there is an 
imbalance between the excitatory and inhibitory neurotransmitters thus decreased amounts of 
dopamine and norepinephrine and an increased amount of serotonin, which normally has an 
inhibitory effect of sexual functioning.1 
 HSDD is relevant to both patients and the PA practice in that it can impact women’s 
quality of life, the amount of money spent on healthcare costs and the number of healthcare visits 
each year due to the disorder. Because of its multifactorial etiology, women suffering from 
HSDD generally need more outpatient visits, radiological services, laboratory work and 
prescription medications to determine its cause.3 Though the exact number of healthcare visits 
and cost each year due to HSDD is unknown, one study estimated that women with HSDD spent 
16.8% more on healthcare when compared to women without the disorder.3  
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 Treatment of HSDD includes looking for underlying etiological causes such as 
depression or a psychiatric disorder, an arousal disorder, an orgasm disorder, cancer, 
uncontrolled hypertension or a side effect from a medication.4 Treatment options vary for 
different etiological causes but generally include seeing a psychotherapist or a sex therapist.4 
Uncontrolled hypertension can easily be treated with medication and lifestyle changes while side 
effects due to a medication can be treated by discontinuing a medication and/or switching to a 
different type of medication. Psychotherapy or a sex therapist can help relieve psychological 
symptoms in patients with HSDD but oral Flibanserin is the first FDA approved medication 
shown to effectively increase the number of SSE in women suffering from HSDD. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not 100mg 
Flibanserin is effective in increasing the number of sexually satisfying events in women with 
HSDD. 
METHODS 
All three studies used in this review required a population of adult females over the age of 18 
years old who had been diagnosed with generalized HSDD. The intervention was the 
implementation of 100mg Flibanserin tablets once daily at bedtime. Comparisons were made 
between those taking 100mg Flibanserin tablets and those taking a placebo pill once daily before 
bedtime. The outcomes measured were the change in the number of sexually satisfying events 
that women reported. All three studies were randomized control trials, double blind and placebo 
controlled studies that compared 100mg Flibanserin PO qhs to Placebo PO qhs.  
 Keywords used when searching for articles included Flibanserin, Hypoactive Sexual 
Desire Disorder, and women. All three articles were published in English in peer-reviewed 
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journals. Articles were obtained through searching keywords in PubMed and were selected based 
on the relevance to the clinical question, being a randomized controlled trial and determining if 
the outcomes mattered to patients. Inclusion criteria for the articles included women over the age 
of 18 with generalized HSDD > 24 weeks, a stable, communicative, monogamous and 
heterosexual relationships for > 1 year with a sexually functional partner who was able to be 
present > 50% of every month and women who were willing to engage in sexual activity at least 
once per month. The three chosen articles had extensive exclusion criteria but the articles 
generally excluded those with a Major Depressive Disorder in the past 6 months, any history of a 
suicide attempt, those with other sexual dysfunction or gynecological disorders that could 
interfere with the study, a history of substance abuse in the past year or taking medications that 
could interfere with sexual dysfunction or cause a drug interaction while taking Flibanserin. 
Additional exclusion criteria includes see a psychotherapist in the past year, history of cancer in 
the past 10 years, a women who is pregnant or breastfeeding or a partner with HSDD. The 
statistics that were utilized and reported in all three studies were mean changes from baseline and 
p-values. Table 1 displays the demographics and characteristics of the included studies.  
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Table 1: Demographics of Characteristics of included studies 
 
 
 
 
 
Study Type # Pts Age Inclusion Exclusion w/d Intervention 
Derogatis 
(2011) 
Double 
Blind, 
Placebo 
Controlled 
RCT 
880 Premenopausal 
over 18 years 
old 
Premenopausal 
women >18 
years of age w/ 
HSDD > 24 
weeks in a 
stable 
monogamous 
heterosexual 
relationship >1 
year  and is 
willing to 
engage in 
sexual activity 
at least once a 
month 
Other sexual dysfunctions 
or gynecological 
disorders, MDD in the 
last 6 months or hx of 
suicide attempt. 
Substance abuse in the 
past year or taking 
medications that could 
interfere with sexual 
dysfunction. Seeing a 
psychotherapist in past 
year. Hx of cancer in the 
past 10 years, Pregnant or 
breastfeeding women or a 
partner w/ HSDD 
217 50mg or 
100mg 
Flibanserin 
qhs 
Katz (2013) Double 
Blind, 
Placebo 
Controlled 
RCT 
1090 Premenopausal 
over 18 years 
old 
Premenopausal 
women >18 
years of age w/ 
HSDD > 24 
weeks in a 
stable 
monogamous 
heterosexual 
relationship >1 
year and is 
willing to 
engage in 
sexual activity 
at least once a 
month activity 
at least once a 
month 
 
Other sexual dysfunctions 
or gynecological 
disorders, MDD in the 
last 6 months or hx of 
suicide attempt. 
Substance abuse in the 
past year or taking 
medications that could 
interfere with sexual 
dysfunction. Seeing a 
psychotherapist in past 
year. Hx of cancer in the 
past 10 years, Pregnant or 
breastfeeding women or a 
partner w/ HSDD 
233 100mg 
Flibanserin 
qhs 
Simon 
(2014) 
Double 
Blind, 
Placebo 
Controlled 
RCT 
949 Postmenopausal 
women of any 
age w/ at least 
one ovary 
Naturally 
postmenopausal 
women of any 
age with HSDD 
lasting 6 
months or more 
and those in a 
stable 
monogamous 
relationship >1 
year 
Beck Inventory 
Depression score of >14 
or suicidal attempts, other 
sexual dysfunctions or 
gynecological disorders 
or  
taking medications that 
could interfere with 
sexual dysfunction or 
cause drug interactions 
 
185 Flibanserin 
100mg qhs 
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OUTCOMES MEASURED 
 A SSE is defined as “sexual intercourse, oral sex, masturbation, or genital stimulation by 
a partner.”1 For all three studies, women were required to keep an eDiary and record their sexual 
activity and whether this activity was satisfying.1 If women had sexual activity she would 
respond to whether or not it was satisfying by responding yes or no. All three studies used a 
Wilcoxon’s rank-sum test for analyzing whether sexual activity was considered a SSE. 
RESULTS 
 All three studies compared the use of 100mg Flibanserin with placebo for the 
symptomatic treatment of HSDD. Two trials were in women > 18 years and older who were 
premenopausal while the third study used women > 18 years old who were postmenopausal. All 
three studies were randomized control trials in which the data was continuous and not converted 
into dichotomous data.  
 The DeRogatis et al study used pre menopausal women >18 years old and had a very 
large list of exclusion criteria (Table 1) that excluded a variety of women with relationship 
problems, gynecological disorders other than HSDD, exclusion of a variety of medications that 
could interfere with the study drug and any pregnancy or mental health concerns. Due to 
HSDD’s multifactorial etiology, researchers felt that many factors had to be excluded that could 
affect any aspect of low libido, other than HSDD, such as hormonal changes, and any 
interactions with the study drug and/or mental health concerns. In this study the subjects were 
randomly selected to be in one of three groups: 50mg Flibanserin, 100mg Flibanserin or Placebo 
all taken qhs, but this paper will solely focus on the 100mg Flibanserin group for consistency 
across all three studies. Results showed that 100mg Flibanserin taken qhs for 24 weeks increased 
the number of SSE in women when compared with the Placebo control group and the results can 
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be found in Table 2.1 The number of SSE was greater in the 100mg Flibanserin group at 3.0±2.8 
when compared to the Placebo group at 2.7±2.8 over a 4 week time period. In Table 3, the mean 
change from baseline of SSE was determined to be 0.8 for the Placebo group and 1.6 for the 
100mg Flibanserin group with a p value <0.01, showing statistical significance. The number of 
women who reported an Adverse Event (AE) from taking the study medication is displayed in 
Table 4. 59.3% of women in the Placebo group reported an AE with 3.4% of these women 
discontinuing the medication while nearly 66.6% of women in the 100mg Flibanserin group 
reported an AE and 11.4% discontinued the study drug due to these events. 
Table 2: Number of SSE in DeRogatis et al Study1 
Type of Treatment # of SSE over 4 weeks 
100mg Flibanserin 3.0±2.8 
Placebo 2.7±2.8 
 
Table 3: Mean change from Baseline of SSE1 
Type of Treatment Mean Change from Baseline 
(Standard Error) 
P value 
100mg Flibanserin 1.6 (0.23) P<0.01 
Placebo 0.8 (0.20) P<0.01 
 
Table 4: AE analysis1 
Type of Treatment Percent of AE reported Percent who discontinued due to 
AE 
100mg Flibanserin 66.6% 3.4% 
Placebo 59.3% 11.4% 
 
 The Katz et al study also studied women > 18 years old who were premenopausal, 
diagnosed with HSDD and included identical inclusion and exclusion criteria to the DeRogatis et 
al study. In this study, subjects were also randomized to a 100mg Flibanserin group or a Placebo 
group and took the study medication qhs for 24 weeks. Results showed that the number of SSE 
was similar in both the Placebo group and the 100mg Flibanserin group as shown in Table 5. The 
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Placebo group had 2.7 SSE while the Flibanserin group had 2.5 SSE over a 4 week time period. 
The mean change from baseline of the number of SSE between the Placebo group and the 100mg 
Flibanserin group was statistically significant with p < 0.001 and the results are shown in Table 
6. The Flibanserin group showed a mean change in baseline of the number of SSE of 2.5 when 
compared to the Placebo group of 1.5. Table 7 shows the number of AE in each treatment group 
and the Placebo group had 50.5% of women reporting an AE and nearly 62.2% of women taking 
100mg Flibanserin reporting an AE. Approximately 3.7% of the placebo group discontinued due 
to an AE while 9.6% of 100mg Flibanserin discontinued the study.  
Table 5: Number of SSE in Katz et al Study2 
Type of Study # of SSE over 4 weeks (SD) 
100mg Flibanserin 2.5(2.5) 
Placebo 2.7(2.9) 
 
Table 6: Mean change from Baseline of SSE2 
Type of Study Mean change from Baseline 
(Std Deviation) 
P value 
100mg Flibanserin 2.5(4.6) P <0.001 
Placebo 1.5(4.5) P<0.001 
 
Table 7: AE Analysis2 
Type of Study % of AE reported Percent who discontinued due 
to AE 
100mg Flibanserin 62.2% 9.6% 
Placebo 50.5% 3.7% 
 
 The Simon et al study used postmenopausal women diagnosed with HSDD, unlike the 
previous two studies which looked at premenopausal women. Women were blindly randomized 
to two different groups which took either Placebo or 100mg Flibanserin qhs daily for 24 weeks. 
The inclusion criteria included postmenopausal women with at least one ovary and the other 
inclusion criteria included in Table 1. Exclusion criteria included similar criteria in both of the 
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previous studies discussed and is also included in Table 1.  The number of SSE between the 
Placebo group and the 100mg group were similar and are displayed in Table 8. Both the placebo 
group and the Flibanserin group showed that the number of SSE over a 4-week period was 2.0. 
The placebo group showed a mean change of SSE from baseline of 0.6 while the Flibanserin 
group showed a 1.0 mean change with a p-value equal to 0.004, showing statistical significance 
and this data is included in Table 9. The number of AE, shown in Table 10, reported in the 
Placebo group was 51.7% with 3.5% of women dropping out compared to the Flibanserin group, 
which reported 63.4% of AE and 8.1% of women dropping out of the study.  
Table 8: Number of SSE in Simon et al Study5 
Type of Study # of SSE over 4 weeks (SD) 
100mg Flibanserin 2.0 (2.2) 
Placebo 2.0 (2.4) 
 
Table 9: Mean change from Baseline of SSE5 
Type of Study Mean change from Baseline 
(Std Deviation) 
P value 
100mg Flibanserin 1.0 (0.1) P =0.004 
Placebo 0.6 (0.1) P=0.004 
 
Table 10: AE Analysis5 
Type of Study % of AE reported Percent who discontinued due 
to AE 
100mg Flibanserin 63.4% 8.1% 
Placebo 51.7% 3.5% 
 
DISCUSSION:  
Flibanserin, or its trademark name Addyi, is a serotonin 1A receptor agonist and a 
serotonin 2A receptor antagonist that is the only FDA approved drug to treat premenopausal 
women diagnosed with HSDD.6 Though the drug is said to improve sexually satisfying events 
and improve sexual desire, it is still widely unknown the mechanism the drug takes to improve 
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symptoms.6 Flibanserin is contraindicated in those with liver impairment, those who drink 
alcohol and those taking moderate to severe CYP3A4 inhibitor medications due to drug 
interactions.7 This drug does contain a Boxed Warning that highlights the risk of both 
hypotension and syncope especially in those consuming alcohol while using the medication.7 
The FDA approved Flibanserin with a risk evaluation and mitigation strategy (REMS), which 
requires both physicians and pharmacists that would prescribe this medication to undergo 
training to ensure adequate patient counseling on the risk of using alcohol.7 Flibanserin was 
previously used in depression studies and failed to show efficacy but subjects reported having a 
decreased sexual dysfunction, which led to studies looking at the use of this drug and HSDD.6  
 Adverse Events were reported in all three studies but a minimal amount of subjects opted 
out of the study due to the AE as seen in Table 4, 7 and 10. Most AEs were mild to moderate 
with no severe AEs due to taking 100mg Flibanserin or the Placebo. The most common side 
effects included dizziness, somnolence and nausea.1,2,3 
 All three studies analyzed showed an increase in the number of SSE in pre- and 
postmenopausal women with HSDD with the use of 100mg Flibanserin versus Placebo. In the 
Katz et al study, though 100mg Flibanserin was shown to increase the number of SSE, the 
magnitude of improvement was found to be less than the DeRogatis et al study or the Katz et al 
study. Postmenopausal women generally have a higher risk of dyspareunia and sexual arousal 
disorders which could have led to a lesser improvement of SSE in postmenopausal women.  
This review supports the use of 100mg Flibanserin in the treatment of HSDD but there a 
considerable amount of limitations to all three studies. In both DeRogatis et al and Katz et al 
extensive exclusion criteria were used such as women in unstable relationships, those diagnosed 
with depression, those with a partner suffering from sexual dysfunction and a long list of 
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contraindicated medications. In Katz et al, nearly 1/3 of all patients screened were ineligible due 
to exclusion criteria.2 In Simon et al, subjects were excluded with similar criteria except the list 
of contraindicated medications was greatly reduced. Though exclusion criteria was used to rule 
out other causes of decreased libido, it’s possible that many women can suffer from HSDD in 
other settings and that these studies were not fully representative of all women.  
CONCLUSION: 
 Based on this systematic review and chosen studies, 100mg Flibanserin is an effective 
treatment for premenopausal and postmenopausal women diagnosed with HSDD. The data found 
in these three studies are consistent with the beneficial effects of Flibanersin as well as its overall 
safety. No serious AEs were judged by researchers to be related to study medications; therefore, 
it should be a consideration when looking to treat patients for HSDD. Though, no serious AEs 
were found, there are some limitations to be considered when prescribing this medication such as 
the use of alcohol and Flibanserin, use of CYP3A4 drugs or liver dysfunction. Physicians should 
be well informed of the contraindications as well as the drug interactions of Flibanserin before 
prescribing it. 
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